Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
PT Hetzer Medical Indonesia Tbk specializes in the manufacturing and distribution of medical instruments and supplies, primarily serving the Indonesian healthcare market. The company differentiates itself through its extensive distribution network across Indonesia and a focus on innovative medical technologies, which positions it to capitalize on the growing demand for healthcare services in the region.
The company generates revenue through the sale of medical devices, consumables, and ongoing maintenance services. Its competitive advantages include a strong distribution network, strategic partnerships with hospitals, and a focus on R&D to develop innovative products tailored to local market needs.
Government healthcare spending in Indonesia
Regulatory approvals for new medical devices
Partnerships with hospitals and healthcare providers
Trends in medical technology adoption
Regulatory changes affecting medical device approvals
Technological disruption from new entrants in the medical supply market
Increased competition from international medical supply companies
Price pressure from generic medical device manufacturers
Negative operating cash flow impacting liquidity
Potential for increased capital expenditures without corresponding revenue growth
moderate - The healthcare sector is generally resilient during economic downturns, but government spending cuts could impact revenue.
Rising interest rates could increase financing costs for expansion and R&D, potentially impacting profitability and valuation multiples.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on external financing.
growth - Investors may be attracted to the company's potential for revenue growth in a rapidly expanding healthcare market.
high - The stock has shown significant price fluctuations, evidenced by a 46% return over the past year.
